<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Triptorelin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Triptorelin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Triptorelin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10018" href="/d/html/10018.html" rel="external">see "Triptorelin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11131" href="/d/html/11131.html" rel="external">see "Triptorelin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F231908"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trelstar Mixject;</li>
<li>Triptodur</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868523"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Decapeptyl;</li>
<li>Trelstar</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1041118"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gonadotropin Releasing Hormone Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F50724182"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bd49784-37fe-43fb-bf63-92207c0b2eef">Central precocious puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central precocious puberty:</b> Children ≥2 years: Triptodur: IM: 22.5 mg once every 24 weeks; discontinue therapy at appropriate age of onset of puberty.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52431630"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, in adult patients, renal impairment increased systemic exposure to triptorelin.</p></div>
<div class="block dohp drugH1Div" id="F52431631"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, in adult patients, hepatic impairment increased systemic exposure to triptorelin.</p></div>
<div class="block doa drugH1Div" id="F231912"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10018" href="/d/html/10018.html" rel="external">see "Triptorelin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="591ace77-ef35-445d-9787-0cf73fedeb51">Assisted reproductive technologies, controlled ovarian hyperstimulation, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Assisted reproductive technologies, controlled ovarian hyperstimulation, adjunctive therapy: </b> Decapeptyl [Canadian product]: <b>SUBQ:</b> Usual dose: 0.1 mg once daily initiated on day 2 or 3 or days 21 to 23 of menstrual cycle (or 5 to 7 days prior to expected onset of menses). Dose may be adjusted according to ovarian response as measured by ovarian ultrasound with or without serum estradiol levels. Treatment is continued until follicles achieve suitable size (typically 4 to 7 weeks).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25aa6c91-5d54-4157-81ab-7c2cfc67e73d">Breast cancer, premenopausal ovarian suppression during adjuvant endocrine therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, premenopausal ovarian suppression during adjuvant endocrine therapy (off-label use): IM:</b> 3.75 mg once every 28 days ± 3 days (in combination with adjuvant endocrine therapy) for ~5 years; if receiving chemotherapy, begin ovarian suppression with the start of chemotherapy (Bellet 2016; Pagani 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="312cc3b8-9ea6-4b41-af8f-2f9b27a00538">Breast cancer, premenopausal ovarian preservation during chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, premenopausal ovarian preservation during chemotherapy (off-label use): IM:</b> 3.75 mg once every 28 days beginning at least 1 week prior to chemotherapy and continuing throughout chemotherapy (Lambertini 2015). <b></b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef12445f-5450-4468-80d0-329501655968">Breast cancer in male patients, hormone receptor–positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in male patients, hormone receptor–positive (off-label use): Note: </b>Should be used in combination with an aromatase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanc</i>
<i>ed or metastatic disease:</i>
<b> IM:</b> 3.75 mg once every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25980944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25980944'])">Ref</a></span>). Endocrine therapy for males with advanced or metastatic, HR+, HER2-negative breast cancer may be sequenced as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88008b8e-9b3f-46c3-a84f-2f504c9b5a9e">Endometrial stromal sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial stromal sarcoma (off-label use): IM:</b> 3.75 mg once every 28 days for ~3 to 5 months (Jin 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Endometriosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Hormonal add-back therapy (eg, estrogens or progestins) is recommended at the start of treatment to reduce bone mineral loss (Dunselman 2014; SOGC [Leyland 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 3.75 mg once every 4 weeks for a total of 6 doses (Bergqvist 1998; Choktanasiri 1996) <b>or</b> 3.75 mg once every 6 weeks for a total of 4 doses (Tse 2000) <b>or</b> 11.25 mg once every 3 months (Donnez 2004). Duration of therapy is not well established (Dunselman 2014) but should be evaluated after 3 months (SOGC [Leyland 2010]); in general, use of GnRH agonists is limited to less than 6 or 12 months due to adverse events (Leone Roberti Maggiore 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cfc2bc20-2906-48e8-bd76-31c0bfd905ea">Paraphilia, males</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paraphilia, males (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May cause an initial increase in androgen concentrations; concomitant antiandrogen therapy (eg, cyproterone, flutamide) is recommended starting 1 week before and continued for the first month after triptorelin initiation (Guay 2009; WFSBP [Thibaut 2020]). Avoid use in patients with severe osteoporosis (especially in patients with prior fracture) or active pituitary disease (WFSBP [Thibaut 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 3.75 mg once monthly (Thibaut 1993; WFSBP [Thibaut 2020]) <b>or </b>11.25 mg every 3 months (Ho 2012; WFSBP [Thibaut 2020]). If therapy is discontinued, rebound elevation in testosterone levels and recurrence of symptoms may occur; follow-on therapy with another agent is recommended (WFSBP [Thibaut 2020]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13531fc0-f759-4ce8-adf1-0f2fb51f128a">Prostate cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b> Trelstar:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 3.75 mg once every 4 weeks <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 11.25 mg once every 12 weeks <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 22.5 mg once every 24 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990442"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, kidney impairment increases systemic exposure to triptorelin.</p></div>
<div class="block doha drugH1Div" id="F50987636"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, hepatic impairment increases systemic exposure to triptorelin.</p></div>
<div class="block adr drugH1Div" id="F231877"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Central precocious puberty:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Reported adverse reactions are for children and adolescents.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Erythema at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Nasopharyngitis</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hot flash, menstruation</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Gastroenteritis</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Influenza</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection-site pruritus, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Anxiety, mood changes</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Otitis externa</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Bronchitis, cough, pharyngitis, sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hot flash (59% to 73%), increased serum glucose</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Skeletal pain (12% to 13%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased blood urea nitrogen</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Chest pain (2%), dependent edema (2%), hypertension (≤4%), lower extremity edema (6%), peripheral edema (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (1%), skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Decreased libido (2%), gynecomastia (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (1%), anorexia (2%), constipation (2%), diarrhea (1%), dyspepsia (2%), nausea (3%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Dysuria (5%), erectile dysfunction (2% to 10%), mastalgia (2%), testicular atrophy (8%), urinary retention (1%), urinary tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hepatic impairment (1%), increased serum alkaline phosphatase (≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Pain at injection site (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (1%), dizziness (1% to 3%), emotional lability (1%), fatigue (2%), headache (2% to 7%), insomnia (≤2%), pain (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (≤2%), back pain (≤3%), lower extremity pain (2% to 5%), lower limb cramp (2%), myalgia (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Conjunctivitis (1%), eye pain (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (2%), dyspnea (1%), pharyngitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%: Neuromuscular &amp; skeletal: Limb pain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, angioedema, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, depression, intracranial hypertension (idiopathic) (Tan 2019), irritability, outbursts of anger, seizure, suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Crying</p></div>
<div class="block coi drugH1Div" id="F231891"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to triptorelin or any component of the formulation, other gonadotropin-releasing hormone (GnRH) agonists or GnRH; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Breastfeeding; undiagnosed abnormal vaginal bleeding (when used for endometriosis).</p></div>
<div class="block war drugH1Div" id="F231874"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). Myocardial infarction, sudden cardiac death and stroke have been reported in men receiving GnRH agonists. ADT may prolong the QT/QTc interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QTc prolongation, congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients with medications known to prolong the QT interval.</p>
<p style="text-indent:-2em;margin-left:4em;">• Decreased bone density: Use with caution in patients with risk factors for decreased bone mineral density; GnRH agonist therapy may increase risk for osteoporosis and bone fractures particularly with prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Angioedema and anaphylactic shock have occurred; discontinue use if severe reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic syndrome: Metabolic changes (such as hyperglycemia, diabetes, hyperlipidemia) may occur; metabolic dysfunction associated steatotic liver disease, including cirrhosis, has also been reported. Hyperglycemia may manifest as diabetes or worsening of glycemic control in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian hyperstimulation syndrome: Decapeptyl [Canadian product]: Ovarian hyperstimulation syndrome (OHSS) is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011). Therapy with gonadotropins should be stopped.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: Pseudotumor cerebri (idiopathic intracranial hypertension) has been reported in pediatric patients receiving GnRH agonists, including triptorelin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Symptoms of emotional lability (eg, crying, irritability, anger, aggression, impatience) have been reported with GnRH agonists, including triptorelin; monitor for the development or worsening of psychiatric symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Seizures have been reported with GnRH agonists, including triptorelin in patients with or without a history of seizures or other conditions or concurrent medications associated with seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Spinal cord compression: Cases of spinal cord compression, which may contribute to weakness or paralysis (possible fatal complications), have been reported; observe patients with metastatic vertebral lesions closely during the first few weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Symptom flare: Transient initial increases in gonadotropins and sex steroids leading to a worsening of symptoms may be observed during the first few weeks of therapy or after subsequent doses. Testosterone levels increased above baseline and then decreased to castrate levels (&lt;50 ng/dL) within 4 weeks. Patients with prostate cancer may experience new or increased bone pain, neuropathy, hematuria, or urethral or bladder outlet obstruction. Female patients with central precocious puberty may experience transient vaginal bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract obstruction: Observe patients with urinary tract obstruction closely during the first few weeks of treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F231886"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trelstar Mixject: 11.25 mg (1 ea); 22.5 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trelstar Mixject: 3.75 mg (1 ea); 11.25 mg (1 ea [DSC]); 22.5 mg (1 ea [DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triptodur: 22.5 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F231870"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324043"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Trelstar Mixject Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.75 mg (per each): $975.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11.25 mg (per each): $2,927.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg (per each): $5,855.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (Triptodur Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22.5 mg (per each): $23,832.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868524"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Decapeptyl: 0.1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trelstar: 3.75 mg (1 ea); 11.25 mg (1 ea); 22.5 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52613982"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IM: Triptodur: Should only be administered by a health care professional; administer immediately after preparation; verify suspension appears milky and homogenous without aggregates before priming needle. Administer Triptodur by IM injection with a thin-walled 21-gauge needle into the buttock or thigh in a steady uninterrupted manner to prevent needle blockages; alternate injection sites.</p></div>
<div class="block adm drugH1Div" id="F231888"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer by IM injection into the buttock at a 90° angle (Trelstar) or into the buttock or thigh (Triptodur); alternate injection sites. Ensure full amount is injected within 10 seconds without interruption (Trelstar). Prior to administration, perform at least 5 inversions with the syringe to resuspend the particles; do not prime the needle (Trelstar). Administer immediately (&lt;2 minutes) after reconstitution. Must be administered by a health care provider.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ: </b>Decapeptyl [Canadian product] is administered by SUBQ injection into the lower abdomen; alternate injection sites. If a dose is missed, it can be administered on the same day; however, do not double doses. Must administer under the supervision of a health care provider.</p></div>
<div class="block hazard drugH1Div" id="F49132735"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F231902"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Trelstar: Store at 20°C to 25°C (68°F to 77°F). Do not freeze MIXJECT system. Administer immediately after reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">Triptodur: Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">Decapeptyl [Canadian product]: Store at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light.</p></div>
<div class="block meg drugH1Div" id="F53739401"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Triptodur: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F208956s010lbl.pdf%23page%3D12&amp;token=ra7janPAv1YRrOFAM9BKICnQYsSnfONxKPrFlpc2IjhpdL%2FKAplIEIXAm3pUBItVal2Y03Y3hCrKvYhO1H0G0pxaEVgBjOqoR2nIum2oSTuB6Huq09jJN%2FAtgXmL5VzQ&amp;TOPIC_ID=120073" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208956s010lbl.pdf#page=12</a></p></div>
<div class="block usep drugH1Div" id="F53569367"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of central precocious puberty (Triptodur: FDA approved in pediatric patients ≥2 years); palliative treatment of advanced prostate cancer (Trelstar: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F56413185"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300181"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F231879"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Flotufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of ADT on the performance of flotufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Androgen Deprivation Therapy Agents may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact of ADT on the performance of gallium Ga 68 PSMA-11 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperprolactinemic Agents: May diminish the therapeutic effect of Triptorelin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Androgen Deprivation Therapy Agents may diminish the diagnostic effect of Piflufolastat F18.  Management: Androgen deprivation therapy (ADT) may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of ADT on the performance of piflufolastat F18 is unknown, but use of alternative agents should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52453799"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When used for assisted reproductive technologies (ART; not an approved use in the US), pregnancy must be ruled out prior to therapy and nonhormonal contraception should be used until menses occurs. Due to the short half-life of triptorelin (formulations used for ART), it is not expected to be present in the maternal serum at the time of embryo transfer.</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, may impair fertility in males of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F231893"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to triptorelin may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Hormonal changes that occur with therapy may increase the risk of pregnancy loss. Therefore, use is contraindicated during pregnancy. Outcome data following inadvertent exposure in early pregnancy are limited (Elefant 1995; Wu 2021).</p></div>
<div class="block mopp drugH1Div" id="F53569357"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Glucose and HbA<sub>1c</sub> (periodically), signs and symptoms of emerging cardiovascular disease; consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients; development/worsening of psychiatric symptoms</p>
<p style="text-indent:-2em;margin-left:2em;">Additional indication-specific monitoring:</p>
<p style="text-indent:-2em;margin-left:4em;">Precocious puberty: Monitor response to therapy with luteinizing hormone (LH) levels after a gonadotropin-releasing hormone (GnRH) or GnRH agonist stimulation test, basal LH, or serum sex steroid levels beginning 1 to 2 months after initiation of therapy, during therapy, and with each subsequent dose; height every 3 to 6 months; bone age (periodically)</p>
<p style="text-indent:-2em;margin-left:4em;">Prostate cancer: Serum testosterone levels, prostate-specific antigen; bone density</p></div>
<div class="block pha drugH1Div" id="F231873"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Triptorelin is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. After chronic and continuous administration, usually 2 to 4 weeks after initiation, a sustained decrease in LH and FSH secretion occurs. When used for assisted reproductive technologies (ART), prevents premature LH surge in women undergoing controlled ovarian hyperstimulation.</p></div>
<div class="block phk drugH1Div" id="F231890"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 30 to 33 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: None</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Unknown; unlikely to involve CYP; no known metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2.8 ± 1.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe renal impairment: 6.6 to 7.7 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic impairment: 7.6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Trelstar: 1 to 3 hours; Triptodur: 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (42% as intact peptide); hepatic</p></div>
<div class="block phksp drugH1Div" id="F51204412"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: There is a decrease in total Cl proportional to decrease in CrCl and increased Vd and half-life. Patients with renal impairment had 2- to 4-fold higher exposure (AUC) values than younger healthy men.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The decrease in triptorelin Cl is more pronounced. Triptorelin half-life increase is similar to renal impairment. Patients with hepatic impairment had 2- to 4-fold higher exposure (AUC) values than younger healthy men.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Triptorelin clearance is partly correlated to total CrCl, which is well known to decrease with age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F231894"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Gonapeptyl</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pamorelin | Pamorelin la | Triptofem</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Triptorelin Acetat</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Gonapeptyl daily | Salvacyl</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Decapeptyl depot | Diphereline</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Gonapeptyl | Gonapeptyl daily | Neo Decapeptyl</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pamorelin la | Salvacyl</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl LP</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Pamorelin | Pamorelin la | Salvacyl | Triptofem</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Diphereline</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Triptofem</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Decapeptyl diario | Decapeptyl mensual | Decapeptyl Semestral | Decapeptyl trimestral | Gonapeptyl diario</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gonapeptyl | Pamorelin | Salvacyl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Decapeptyl LP | Salvacyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Salvacyl</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Arvekap | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Diphereline p.r.</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline | Gonapeptyl | Pamorelin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Pamorelin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Decapeptyl 6 month</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Diphereline</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Agotrig | Decapeptyl | Gonapeptyl | Pamorelin la</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Fertipeptil | Gonapeptyl</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline p.r. | Diphereline sr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Diphereline</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Gonapeptyl</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Pamorelin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline p.r. | Pamorelin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Decapeptyl cr | Pamorelin | Salvacyl | Triptofem | Triptoreline acetaat | Triptoreline bmodesto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Decapeptyl depot | Gonapeptyl | Pamorelin | Salvapar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Diphereline | Gonapeptyl daily | Triptorelina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline | Pamorelin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Trelstar | Triptodur</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Gonapeptyl daily</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Diphereline PR 1-Month | Diphereline PR 3-Month | Gonapeptyl | Gonapeptyl Depot</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diferelin | Diphereline | Triptorelin long</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline p.r.</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gonapeptyl | Moapar | Pamorelin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline | Pamorelin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Diphereline | Gonapeptyl | Pamorelin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Diphereline | Diphereline p.r.</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Pamorelin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl | Diphereline</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Decapeptyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gonapeptyl daily</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20567196">
<a name="20567196"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 114: Management of endometriosis. <i>Obstet Gynecol.</i> 2010;116(1):223-236. doi:10.1097/AOG.0b013e3181e8b073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/20567196/pubmed" id="20567196" target="_blank">20567196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19959075">
<a name="19959075"></a>Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. <i>Lancet Oncol</i>. 2009;10(12):1188-1198. doi:10.1016/S1470-2045(09)70226-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/19959075/pubmed" id="19959075" target="_blank">19959075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26729437">
<a name="26729437"></a>Bellet M, Gray KP, Francis PA, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST Substudy. <i>J Clin Oncol.</i> 2016;34(14):1584-1593. doi:10.1200/JCO.2015.61.2259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/26729437/pubmed" id="26729437" target="_blank">26729437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9548161">
<a name="9548161"></a>Bergqvist A, Bergh T, Hogström L, Mattsson S, Nordenskjöld F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. <i>Fertil Steril.</i> 1998;69(4):702-708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/9548161/pubmed" id="9548161" target="_blank">9548161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15516445">
<a name="15516445"></a>Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. <i>Obstet Gynecol.</i> 2004;104(5 Pt 2):1182-1184. doi:10.1097/01.AOG.0000133533.05148.aa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/15516445/pubmed" id="15516445" target="_blank">15516445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. <i>J Clin Oncol.</i> 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884586">
<a name="26884586"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline update on ovarian suppression. <i>J Clin Oncol.</i> 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/26884586/pubmed" id="26884586" target="_blank">26884586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8889631">
<a name="8889631"></a>Choktanasiri W, Boonkasemsanti W, Sittisomwong T, et al. Long-acting triptorelin for the treatment of endometriosis. <i>Int J Gynaecol Obstet.</i> 1996;54(3):237-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/8889631/pubmed" id="8889631" target="_blank">8889631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi:10.1016/S1701-2163(15)30417-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Decapeptyl.1">
<a name="Decapeptyl.1"></a>Decapeptyl (triptorelin) [product monograph]. North York, Ontario, Canada: Ferring Inc; July 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980944">
<a name="25980944"></a>Di Lauro L, Pizzuti L, Barba M, et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>J Hematol Oncol</i>. 2015;8:53. doi:10.1186/s13045-015-0147-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/25980944/pubmed" id="25980944" target="_blank">25980944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14967363">
<a name="14967363"></a>Donnez J, Dewart PJ, Hedon B, et al. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. <i>Fertil Steril</i>. 2004;81(2):297-304. doi:10.1016/j.fertnstert.2003.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/14967363/pubmed" id="14967363" target="_blank">14967363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24435778">
<a name="24435778"></a>Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. <i>Hum Reprod.</i> 2014;29(3):400-412. doi:10.1093/humrep/det457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/24435778/pubmed" id="24435778" target="_blank">24435778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7720926">
<a name="7720926"></a>Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F. Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline. <i>Fertil Steril.</i> 1995;63(5):1111-1113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/7720926/pubmed" id="7720926" target="_blank">7720926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531097">
<a name="22531097"></a>Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi:10.1186/1477-7827-10-32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/22531097/pubmed" id="22531097" target="_blank">22531097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34303806">
<a name="34303806"></a>Gronchi A, Miah AB, Dei Tos AP, et al; ESMO Guidelines Committee, EURACAN and GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/34303806/pubmed" id="34303806" target="_blank">34303806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19243704">
<a name="19243704"></a>Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. <i>Clin Ther</i>. 2009;31(1):1-31. doi:10.1016/j.clinthera.2009.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/19243704/pubmed" id="19243704" target="_blank">19243704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926625">
<a name="22926625"></a>Ho DK, Kottalgi G, Ross CC, Romero-Ulceray J, Das M. Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital. <i>J Clin Psychopharmacol</i>. 2012;32(5):739-740. doi:10.1097/JCP.0b013e318266c6f5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/22926625/pubmed" id="22926625" target="_blank">22926625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26131171">
<a name="26131171"></a>Jin Y, Li Y, Deng CY, et al. Fertility-sparing treatment of low-grade endometrial stromal sarcoma. <i>Int J Clin Exp Med</i>. 2015;8(4):5818-5821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/26131171/pubmed" id="26131171" target="_blank">26131171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22416285">
<a name="22416285"></a>Joint Society of Obstetricians and Gynaecologists of Canada -Canadian Fertility and Andrology Society (SOGC-CFAS ) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/22416285/pubmed" id="22416285" target="_blank">22416285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26720025">
<a name="26720025"></a>Lambertini M, Boni L, Michelotti A, et al; GIM Study Group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. <i>JAMA</i>. 2015;314(24):2632-2640. doi:10.1001/jama.2015.17291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/26720025/pubmed" id="26720025" target="_blank">26720025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24832495">
<a name="24832495"></a>Leone Roberti Maggiore U, Scala C, Remorgida V, et al. Triptorelin for the treatment of endometriosis. <i>Expert Opin Pharmacother.</i> 2014;15(8):1153-1179. doi:10.1517/14656566.2014.916279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/24832495/pubmed" id="24832495" target="_blank">24832495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124128">
<a name="20124128"></a>Levine GN, D’Amico AV, Berger P, et al. Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association. <i>Circulation</i>. 2010;121:831-838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/20124128/pubmed" id="20124128" target="_blank">20124128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21545757">
<a name="21545757"></a>Leyland N, Casper R, Laberge P, Singh SS; SOGC. Endometriosis: diagnosis and management. <i>J Obstet Gynaecol Can.</i> 2010;32(7)(suppl 2):S1-S32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/21545757/pubmed" id="21545757" target="_blank">21545757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24881463">
<a name="24881463"></a>Pagani O, Regan MM, Walley BA, et al; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. <i>N Engl J Med.</i> 2014;371(2):107-118. doi:10.1056/NEJMoa1404037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/24881463/pubmed" id="24881463" target="_blank">24881463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi:10.1016/j.fertnstert.2016.08.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10986575">
<a name="10986575"></a>Reilly DR, Delva NJ, Hudson RW. Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia. <i>Can J Psychiatry</i>. 2000;45(6):559-563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/10986575/pubmed" id="10986575" target="_blank">10986575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes [published online November 18, 2019]. <i>Am J Clin Dermatol</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8356897">
<a name="8356897"></a>Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. <i>Acta Psychiatr Scand</i>. 1993;87(6):445-450. doi:10.1111/j.1600-0447.1993.tb03402.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/8356897/pubmed" id="8356897" target="_blank">8356897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20459370">
<a name="20459370"></a>Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM; WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. <i>World J Biol Psychiatry</i>. 2010;11(4):604-655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/20459370/pubmed" id="20459370" target="_blank">20459370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32452729">
<a name="32452729"></a>Thibaut F, Cosyns P, Fedoroff JP, Briken P, Goethals K, Bradford JMW; WFSBP Task Force on Paraphilias. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. <i>World J Biol Psychiatry</i>. 2020;21(6):412-490. doi:10.1080/15622975.2020.1744723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/32452729/pubmed" id="32452729" target="_blank">32452729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TrelstarMix.1">
<a name="TrelstarMix.1"></a>Trelstar Mixject (triptorelin) [prescribing information]. Ewing, NJ: Verity Pharmaceuticals Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trelstar.2">
<a name="Trelstar.2"></a>Trelstar 3.75, 11.25, and 22.5 mg (triptorelin) [product monograph]. Montreal, Qebec, Canada: Knight Therapeutics Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Triptodur.1">
<a name="Triptodur.1"></a>Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11025843">
<a name="11025843"></a>Tse CY, Chow AM, Chan SC. Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study. <i>Hong Kong Med J.</i> 2000;6(3):260-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/11025843/pubmed" id="11025843" target="_blank">11025843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf" target="_blank">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33743741">
<a name="33743741"></a>Wu H, Xu X, Ma C, et al. No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a retrospective analysis. <i>Reprod Biol Endocrinol</i>. 2021;19(1):46. doi:10.1186/s12958-021-00732-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triptorelin-pediatric-drug-information/abstract-text/33743741/pubmed" id="33743741" target="_blank">33743741</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120073 Version 103.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
